A carregar...
Rucaparib and Niraparib in Advanced Ovarian Cancer
Rucaparib and niraparib are two of the newest U.S. Food and Drug Administration–approved PARP inhibitors, joining olaparib with indications in ovarian cancer. Both drugs have led to meaningful responses when used as monotherapy in previously treated ovarian cancers, with niraparib demonstrating acti...
Na minha lista:
| Publicado no: | J Adv Pract Oncol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Harborside Press LLC
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7520743/ https://ncbi.nlm.nih.gov/pubmed/33343988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.4.8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|